Nuvalence

Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The company utilizes a proprietary chemistry-driven, structure-based drug design platform to develop small molecule inhibitors that address the limitations of existing therapies, such as drug resistance and off-target toxicities. Their lead candidates, zidesamtinib (NVL-520) and alvesamtinib (NVL-655), are currently in pivotal Phase 2 clinical trials for ROS1-positive and ALK-positive non-small cell lung cancer, respectively. Nuvalent's molecules are specifically engineered to be highly selective, brain-penetrant, and active against common resistance mutations. By focusing on high-selectivity and overcoming drug resistance, the company aims to provide more durable clinical responses for patients with oncogenic drivers.